IGRA

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

Global Latent TB Testing Market Analysis Report 2023-2029: Amplify the Incorporation of Technological Advancement in Dx Laboratories, Increase the R&D Spending to Improve the Efficacy of Testing Rates - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Health, Infectious Diseases, TST, TB, Risk, Research, LTBI, WHO, Prevalence, Education, USD, Laboratory, Infection, National library, IGRA, Research report

The Global Latent TB Testing Market is expected to generate USD 3.93 Billion by the end of 2029, up from USD 1.8 Billion in 2022.

Key Points: 
  • The Global Latent TB Testing Market is expected to generate USD 3.93 Billion by the end of 2029, up from USD 1.8 Billion in 2022.
  • During the forecast period, 2024-2029, Global Latent TB Testing is expected to expand at a CAGR of 12%.
  • A favourable growth element for the global Latent TB Testing market is propelled by government initiatives and policies, raising awareness and education, and technological advancements in testing methods.
  • These technologies often offer enhanced sensitivity, specificity, and faster turnaround times, improving the overall efficiency of latent TB testing.

Playtech's PAM solution and Anaxi™ Class II Slots Games to Further Enhance the Tribal Gaming Experience

Retrieved on: 
Tuesday, December 12, 2023
National Indian Gaming Commission, Anaxis, Jim Cramer, Aristocracy (class), WinStar World Casino, PAM, Class, Partnership, NIGC, IGRA, Josh Morris, RGS, Casino, Resort, Playtech

Class II Mobile-on-Premise gaming is an advancement in the tribal gaming industry within the United States and it incorporates a combination of Bingo and non-banked card games, making it the first of its kind.

Key Points: 
  • Class II Mobile-on-Premise gaming is an advancement in the tribal gaming industry within the United States and it incorporates a combination of Bingo and non-banked card games, making it the first of its kind.
  • Playtech and Anaxi will merge their expertise in Playtech's Player Account Management (PAM) solution and Mobile Gaming Application Development with Anaxi Class II Slots games to support the growing requirements of tribal gaming.
  • We are thrilled to be at the forefront of supporting innovation in tribal gaming supporting a cutting-edge, Class II Mobile-on-Premise gaming experience for the very first time.
  • We firmly believe that Anaxi's Remote Game Server (RGS) and Class II Slots game, combined with Playtech's seamless integration of their PAM solution and WinStar World Casino and Resort's on-property casino amenities, will provide an immersive experience that exceeds gaming patron's expectations.

Latent Tuberculosis Testing Market Set to Reach $1.96 Billion in 2023 with a CAGR of 5.95% - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Health, Infectious Diseases, LTBI, Ageing, MDR-TB, Acid test (gold), NAAT, Tuberculosis, Johnson & Johnson Pharmaceutical Research and Development, TB, Prevalence, HIV, Urbanization, Research, Spectroscopy, Smoking, Smoker, Trendsetter, Growth, Immune system, COVID-19, Risk, Hospital, Pharmacy, Investment, Diagnosis, IGRA, Tobacco, Infection, Pharmaceutical industry, Vaccine, Fine chemical, Medical imaging, Tuberculin

Latent tuberculosis, a condition where tuberculosis bacteria remain dormant within the body, presents a unique challenge in healthcare.

Key Points: 
  • Latent tuberculosis, a condition where tuberculosis bacteria remain dormant within the body, presents a unique challenge in healthcare.
  • By Type: The LTBI testing market is segmented into Tuberculin skin test LTBI testing and interferon gamma released assay (IGRA).
  • Geographic Coverage: The global LTBI testing market spans North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
  • The global LTBI testing market features a moderately fragmented landscape, with numerous small- and medium-sized manufacturers contributing significantly.

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

Retrieved on: 
Wednesday, October 4, 2023
Vaccine, IGRA, DNA, QIAGEN, QGEN, Central nervous system, Senior, EBV, SARS-CoV-2, COVID-19, Nonpathogenic organisms, Cytomegalovirus, Research, Post-transplant lymphoproliferative disorder, Multiple sclerosis, Antibody, Lyme, MS, DiaSorin, Infectious mononucleosis, QuantiFERON, RUO, HIV disease progression rates, Patient, Risk, Blood, PTLD, Immune system, Gamma ray, Lymphocyte, Health, Virus, NYSE, Epstein–Barr virus infection, Autoimmunity, Conditional sentence, Dentistry

Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.

Key Points: 
  • Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.
  • In organ transplant recipients, EBV is associated with post-transplant lymphoproliferative disorder (PTLD), a potentially fatal complication after solid organ transplantation.
  • Measuring the T-cell response to EBV can help researchers better understand immune responses to the virus.
  • This approach is different from but complementary to traditional tests, which focus on detecting viral DNA or antibodies produced in response to the virus.

QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

Retrieved on: 
Thursday, June 15, 2023
Infection, TST, Systematic review, IGRA, CCLM, Tuberculosis, QIAGEN, QGEN, Medical laboratory, International, Comparison, Vaccination, Workflow, World Health Organization's response to the COVID-19 pandemic, Clinical Chemistry and Laboratory Medicine, Meta-analysis, CDC, BCG, Death, QuantiFERON, CD8, Padjadjaran University, Patient, Gold, Risk, Gamma ray, Diagnosis, CD4, TB2, Genetically modified bacteria, Immunodeficiency, Lymphocyte, WHO, NYSE, World Health Organization, Disease, Vaccine, Pharmaceutical industry, TB

The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).

Key Points: 
  • The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).
  • The meta-analysis on QuantiFERON testing was conducted by Universitas Padjadjaran, Indonesia, and published in Clinical Chemistry and Laboratory Medicine (CCLM) [1] .
  • QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually.
  • [1] Darmawan, Guntur et al: "Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB Gold Plus: a meta-analysis" Clinical Chemistry and Laboratory Medicine (CCLM), 2023. https://doi.org/10.1515/cclm-2023-0293

QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

Retrieved on: 
Wednesday, May 3, 2023
Infection, TST, IGRA, Tuberculosis, Disease, QIAGEN, QGEN, Risk, Evidence-based medicine, Vaccination, Workflow, COVID-19, QFT, BCG, Affordable Care Act, Patient, Laboratory, Physician, Gold, Genetically modified bacteria, Lymphocyte, WHO, Care Act 2014, NYSE, LTBI, World Health Organization, USPSTF, Vaccine, Pharmaceutical industry, TB

Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk.

Key Points: 
  • Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk.
  • The USPSTF recommendations referred to QuantiFERON-TB Gold Plus (QFT-Plus) from QIAGEN as reliable in screening.
  • It also suggested that interferon gamma release assays (IGRAs) like QFT-Plus may have advantages in certain patient populations over the tuberculin skin test (TST) in a wider group of people at risk for latent TB infection.
  • This ongoing recommendation from the USPSTF supports the continued use of QuantiFERON-TB Gold Plus as part of the global fight against TB.

SAN MANUEL BAND OF MISSION INDIANS HIRES FORMER NATIONAL INDIAN GAMING COMMISSION GENERAL COUNSEL MICHAEL HOENIG TO JOIN TRIBE’S IN-HOUSE LEGAL TEAM

Retrieved on: 
Tuesday, January 24, 2023
Indian country, Indian Gaming Regulatory Act, Commission, Legal Department (Hong Kong), Mission Indians, National Indian Gaming Commission, Country, San Manuel Band of Mission Indians, IGRA, NIGC, General counsel, Associate, Hunting, Tribe

In his new role, Michael will provide guidance and counsel on developments related to gaming and other matters arising under the Indian Gaming Regulatory Act (IGRA), as well as on general issues of federal Indian law.

Key Points: 
  • In his new role, Michael will provide guidance and counsel on developments related to gaming and other matters arising under the Indian Gaming Regulatory Act (IGRA), as well as on general issues of federal Indian law.
  • Michael joins San Manuel from the National Indian Gaming Commission (NIGC), where he was NIGC’s longest serving General Counsel.
  • His service at the NIGC spanned 16 years through the roles of Staff Attorney, Senior Attorney, Associate General Counsel, and finally, General Counsel.
  • We are delighted Michael has chosen to join San Manuel’s in-house legal team,” said San Manuel’s Chief Legal and Compliance Officer Erin Copeland.

Tuberculosis Testing Global Market Report 2022: Global Tuberculosis Efforts to Drive Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Health, Pharmaceutical, COVID-19, Tuberculosis, Growth, CAGR, IGRA, Interferon, Pharmaceutical industry, Pet

The "Tuberculosis Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tuberculosis Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Culture-Based Tests, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$634.3 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $117.7 Million, While China is Forecast to Grow at 5.4% CAGR
    The Tuberculosis Testing market in the U.S. is estimated at US$117.7 Million in the year 2020.
  • In the global Interferon-Gamma Release Assay (IGRA) segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment.

Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, COVID-19, Other Science, Clinical Trials, General Health, Science, Movement, Tuberculosis, Cancer, Company, Preventive healthcare, Non-functional testing, Spectroscopy, LabCorp, Prevalence, Infection, TST, Naʽat, Disulfiram-like drug, MDR-TB, CAGR, IGRA, Center, COVID-19, Institutionalisation, Ageing, Health, Immune system, Growth, LTBI, HIV, Pharmacy, Bacteria, TB, Immunosuppression, CDC, Patient, Diagnosis, Risk, Interferon, Urbanization, Cdx, Centers for Disease Control and Prevention timeline, Population, Pharmaceutical industry, Vaccine, Tobacco, Medical device, Fine chemical, Heating, ventilation, and air conditioning

The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global latent tuberculosis infection (LTBI) testing market in 2021 was valued at US$1.75 billion and is expected to reach US$2.47 billion by 2027, growing at a CAGR of 5.95% during 2022-2027.
  • One of the most important factors impacting the global latent tuberculosis infection (LTBI) testing market is aging population.
  • As the aging population grows further, the risk of latent tuberculosis prevalence among them also tends to increase, which is expanding the scope for the growth of the global latent tuberculosis infection testing market in coming years.